UTHR - United Therapeutics GAAP EPS of $4.86 beats by $0.36 revenue of $506.9M misses by $7.47M

2023-05-03 06:05:34 ET

• United Therapeutics press release ( NASDAQ: UTHR ): Q1 GAAP EPS of $4.86 beats by $0.36 .
• Revenue of $506.9M (+9.7% Y/Y) misses by $7.47M .
• “The hard work and determination of our over 1,000 Unitherians during the first quarter of this year allowed us to reach over $500 million in revenue for the second quarter ever,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer. “And to sustain our mission to help patients in need, our clinical team continues to progress our four registration studies in progress: the two TETON studies of Tyvaso in idiopathic pulmonary fibrosis, the ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension, and the clinical study of our CLES ex vivo lung perfusion technology.”

For further details see: